04:30 PM EST, 03/07/2024 (MT Newswires) -- KalVista Pharmaceuticals ( KALV ) said Thursday that Benjamin Palleiko was named chief executive officer, effective immediately.

He succeeds Andrew Crockett, who stepped down.

Palleiko was chief financial officer, chief business officer and president.

"This appointment is the result of a planned transition as KalVista prepares to become a commercial entity following the success of the Konfident phase 3 trial for its potential oral therapy for hereditary angioedema and a planned US new drug application" in H1, according to a company statement.

Shares of KalVista fell 1.7% in after-hours trading.

Price: 13.77, Change: -0.23, Percent Change: -1.68